

PROGRAM
FOR THE DOCTORAL THESIS SEMINAR # 902.218

COORDINATION:
PROF. DR. ANNA REPIC, PROF. DR. JOHANNES HUPPA, DR. PHILIPP
SCHATZLMAIER, DR. RENÉ PLATZER, PROF. DR. HANNES
STOCKINGER

TOPIC FOR THE WINTER SEMESTER 2021/2022:

TUMOUR IMMUNOLOGY AND CANCER IMMUNOTHERAPY

VENUE: VIRTUAL MEETING VIA WEBEX

TIME: JANUARY 31-FEBRUARY 1, 2022

DAY 1: MONDAY JANUARY 31:

MEETING LINK:

[HTTPS://MEDUNIWIEN.WEBEX.COM/MEDUNIWIEN/J.PHP?MTID=MFC17EFF4FDAA481E0095D2670F6A2BD](https://meduniwien.webex.com/meduniwien/j.php?mtid=mfcd17eff4fdaa481e0095d2670f6a2bd), MEETING NUMBER (ACCESS CODE): 2734 900 6241,
MEETING PASSWORD: D7NKGVP5KH7 (37654875 FROM VIDEO SYSTEMS)

- | | |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11.00 – 11.15 | COORDINATORS (+ VLADIMIR LEKSA)
WELCOME, INTRODUCTION TO AND OVERVIEW OF THE TOPIC |
| 11.15 – 11.35 | PHILIPP BRUNMAYR
HALLMARKS OF CANCER, GENERAL ASPECTS OF CELLULAR TRANSFORMATION, TYPES OF CANCER (INTRODUCTORY LECTURE) |
| 11.35 – 11.50 | DISCUSSION |
| 11.50 – 12.10 | LENA WAGNER
IMMUNOSURVEILLANCE, IMMUNOEDITING AND TUMOUR EVASION MECHANISMS (PLUS EFFECTS OF THE TUMOR ON LOCAL AND SYSTEMIC IMMUNE REGULATION) |
| 12.10 – 12.25 | DISCUSSION |
| 12.25 – 12.50 | LUNCH BREAK |
| 12.50 – 13.10 | VANESSA MÜHLGRABNER
TILS: WHAT THEY ARE, DO AND RECOGNIZE |
| 13.10 – 13.25 | DISCUSSION |
| 13.25 – 13.45 | ANGELIKA PLACH
ROLE OF TUMOR-ASSOCIATED LYMPHOCYTES (TREG, BREG) AND IGG4 ANTIBODIES IN CANCER PROGRESSION |
| 13.45 – 14.00 | DISCUSSION |
| 14.00 – 14.20 | PHILIPP SCHATZLMAIER
INFLAMMAGING, CHRONIC INFECTIONS AND CANCER |
| 14.20 – 14.35 | DISCUSSION |

- 14.35 – 14.55 **GABOR TAJTI**
 IN THE HOOD - TUMOR MICROENVIRONMENT AS A WAY TO HIDE FROM THE IMMUNE SYSTEM (SUPPORTIVE STROMAL CELLS, EXTRACELLULAR MATRIX, TUMOR VASCULATURE, GENETIC PROFILE OF IMMUNE CELLS WITHIN THE TUMOR MASS, ETC.)
- 14.55 – 15.10 DISCUSSION
- 15.10 – 15.30 **MALGORZATA KUPC**
 USABILITY, DIFFERENCES AND IMMUNOLOGICAL RELEVANCE OF VARIOUS CANCER MODELS (CELL LINES VS. SPHEROIDS/ORGANOIDS VS. EX VIVO TUMOUR EXPLANTS VS. (ORTHOTOPIC) XENOGRAFTS IN MICE SPONTANEOUS TUMOURS IN MICE)
- 15.30 – 15.45 DISCUSSION

DAY 2: TUESDAY FEBRUARY 1:

MEETING LINK:

[HTTPS://MEDUNIWIEN.WEBEX.COM/MEDUNIWIEN/J.PHP?MTID=MF107F357D676C8A277312109F5E6A9BC](https://meduniwiien.webex.com/meduniwiien/j.php?mtid=MF107F357D676C8A277312109F5E6A9BC), MEETING NUMBER (ACCESS CODE): 2734 763 3118, MEETING PASSWORD: VVH3CPJ7HY4 (88432757 FROM VIDEO SYSTEMS)

- 11.00 – 11.20 **ANNA REPIC (+ INTRODUCTION TO DAY 2)**
 ROLE OF INNATE IMMUNITY IN CANCER, TUMOUR-ASSOCIATED MYELOID CELLS WITH IMMUNOSUPPRESSIVE FUNCTIONS (MDSC, TAM, TAN)
- 11.20 – 11.35 DISCUSSION
- 11.35 – 11.55 **ROMANA PRAŽENICOVÁ**
 CANCER VACCINATION (PEPTIDE- OR RNA-BASED) AND EX VIVO AND IN VIVO STRATEGIES FOR DENDRITIC CELL-BASED IMMUNOTHERAPY
- 11.55 – 12.10 DISCUSSION
- 12.10 – 12.30 **RENÉ PLATZER**
 ANTIBODY-BASED THERAPY IN CANCER: IMMUNE CHECKPOINT INHIBITORS, BITES, IMMUNOCONJUGATES, ADCC ETC.
- 12.30 – 12.45 DISCUSSION
- 12.45 – 13.10 **BREAK**
- 13.10 – 13.20 **venu GUDIPATI**
 CHIMERIC (ANTIBODY-BASED) ANTIGEN RECEPTOR (CAR) IMMUNOTHERAPY (DIFFERENCES IN DIFFERENT CAR GENERATIONS, CAR T CELL THERAPY IN THE CLINIC (+INDICATIONS), AND IN DEVELOPMENT)
- 13.20 – 13.35 DISCUSSION
- 13.35 – 13.55 **LUCAS TEUSCHL**
 ONE SIZE FITS ALL CELL THERAPY? MR1-T CELLS, NK CELLS, GAMMA-DELTA T CELLS, ETC.
- 13.55 – 14.10 DISCUSSION

- 14.10 – 14.20 **LAURA GEBETSBERGER**
ONCOLYTIC VIRUS THERAPY
- 14.20 – 14.35 DISCUSSION
- 14.35 – 14.55 **MILENA WEBER**
FUTURE TRENDS IN CANCER IMMUNE THERAPY (TCR-
ENGINEERING, COMBINATION THERAPIES, NANOMEDICINE-
BASED THERAPIES, MRNA VACCINES, ETC.)
- 14.55 – 15.10 DISCUSSION
- 15.10 – 15.40 **FINAL DISCUSSION**

ADDITIONALLY, THE FOLLOWING TALK WILL BE GIVEN AT ONE OF THE NEXT LAB MEETINGS (IN FEBRUARY 2022)

TIMO PETERS

TUMOR ANTIGENS AND IMMUNOGENICITY: FUNDAMENTAL DIFFERENCES BETWEEN TCR- AND ANTIBODY/CAR-MEDIATED RECOGNITION, ON THE ROLE OF ALLELIC HLA-VARIABILITY AND OTHER GENETIC PREDISPOSITIONS TO RECOGNIZING TUMOR ANTIGENS